Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors

First integrin inhibitor since Tysabri nears approval for IBD

(2014) Cormac Sheridan   NATURE BIOTECHNOLOGY

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY

The Immunologic Functions of the Neonatal Fc Receptor for IgG

(2012) Timo Rath et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

(2011) Tsunehiro Mizushima et al.   GENES TO CELLS

Crystal Structure of Fcγ Receptor I and Its Implication in High Affinity γ-Immunoglobulin Binding

(2011) Jinghua Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

(2011) P. A. Ramsland et al.   JOURNAL OF IMMUNOLOGY

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Production of therapeutic antibodies with controlled fucosylation

(2010) Naoko Yamane-Ohnuki et al.   mAbs

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Engineered therapeutic antibodies with improved effector functions

(2009) Tsuguo Kubota et al.   CANCER SCIENCE

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

(2009) Mami Shibata-Koyama et al.   EXPERIMENTAL HEMATOLOGY

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Glycosylation as a strategy to improve antibody-based therapeutics

(2009) Roy Jefferis   NATURE REVIEWS DRUG DISCOVERY

The N-linked oligosaccharide at Fc RIIIa Asn-45: an inhibitory element for high Fc RIIIa binding affinity to IgG glycoforms lacking core fucosylation

(2008) M. Shibata-Koyama et al.   GLYCOBIOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY